Investigational Drug Information for Belotecan
✉ Email this page to a colleague
What is the development status for investigational drug Belotecan?
Belotecan is an investigational drug.
There have been 7 clinical trials for Belotecan.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2009.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Ovarian Neoplasms. The leading clinical trial sponsors are Chong Kun Dang Pharmaceutical, Sokbom Kang, and Yonsei University.
Summary for Belotecan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 2,475 |
| WIPO Patent Applications | 1,779 |
| Japanese Patent Applications | 237 |
| Clinical Trial Progress | Phase 3 (2009-01-01) |
| Vendors | 33 |
Recent Clinical Trials for Belotecan
| Title | Sponsor | Phase |
|---|---|---|
| A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer | Gachon University Gil Medical Center | Phase 1/Phase 2 |
| Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial | Chong Kun Dang Pharmaceutical | Phase 2 |
| A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer | Chong Kun Dang Pharmaceutical | Phase 2 |
Clinical Trial Summary for Belotecan
Top disease conditions for Belotecan
Top clinical trial sponsors for Belotecan
US Patents for Belotecan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
